MaryEapenMD

Associate Professor, Medicine, Medical College of Wisconsin

Are you Dr. Eapen?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
9000 W Wisconsin Ave
Division Of Pediatric Hematology/Oncology
Milwaukee, WI 53226
Phone+1 414-456-4170

Fax+1 414-456-6543

Dr. Mary Eapen, MD is a pediatric hematologist/oncologist in Milwaukee, Wisconsin. She is currently licensed to practice medicine in Wisconsin and Minnesota. She is an Associate Professor at Medical College of Wisconsin.

PubMed

Hematopoietic cell transplant compared with standard care in adolescents and young adults with sickle cell disease.
Mark C Walters, Mary Eapen, Yiwen Liu, Fuad El Rassi, Edmund K Waller
Blood Advances. 2025-03-11
Haploidentical Bone Marrow Transplantation for Sickle Cell Disease.
Adetola A Kassim, Mark C Walters, Mary Eapen, Madoc Smith, Brent R Logan
NEJM Evidence. 2025-03-01
Platelet-Targeted Gene Therapy for Hemophilia A with Inhibitor History.
Mary Eapen, Lynn M Malec, Myriam A Armant, Bryon D Johnson, Qizhen Shi
The New England Journal of Medicine. 2025-01-23

Researchers Develop a Validated Pediatric Disease Risk Index for AML and ALLFebruary 1st, 2021
Navigating Treatment Options and Communication in Relapsed Pediatric AMLJune 17th, 2024

Medical College of Wisconsin Physician Scientist Immersion ProgramMEDICAL COLLEGE OF WISCONSIN2023–2028
Cure Sickle CellMEDICAL COLLEGE OF WISCONSIN2018–2026
Cure Sickle CellMEDICAL COLLEGE OF WISCONSIN2018–2026
Cure Sickle CellMEDICAL COLLEGE OF WISCONSIN2018–2026
Cure Sickle CellMEDICAL COLLEGE OF WISCONSIN2018–2026
Cure Sickle CellMEDICAL COLLEGE OF WISCONSIN2018–2026
Cure Sickle CellMEDICAL COLLEGE OF WISCONSIN2018–2026
Cure Sickle CellMEDICAL COLLEGE OF WISCONSIN2018–2026
Cure Sickle CellMEDICAL COLLEGE OF WISCONSIN2018–2026
A Phase I Clinical Trial Testing Feasibility of Hematopoietic Stem Cell Gene Therapy Using Platelet Factor VIII to Safely Improve Hemostasis for Severe Hemophilia A with Inhibitory AntibodiesMEDICAL COLLEGE OF WISCONSIN2019–2025
A Phase I Clinical Trial Testing Feasibility of Hematopoietic Stem Cell Gene Therapy Using Platelet Factor VIII to Safely Improve Hemostasis for Severe Hemophilia A with Inhibitory AntibodiesMEDICAL COLLEGE OF WISCONSIN2019–2025
A Phase I Clinical Trial Testing Feasibility of Hematopoietic Stem Cell Gene Therapy Using Platelet Factor VIII to Safely Improve Hemostasis for Severe Hemophilia A with Inhibitory AntibodiesMEDICAL COLLEGE OF WISCONSIN2019–2025